Related Experiment Video

Updated: Jun 1, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

Bortezomib stabilizes NOXA and triggers ROS-associated apoptosis in medulloblastoma

Sachiko Ohshima-Hosoyama1, Monika A Davare, Tohru Hosoyama

  • 1Greehey Children's Cancer Research Institute, University of Texas Health Science Center, San Antonio, TX 78229, USA.

Journal of Neuro-Oncology
|June 3, 2011
PubMed

Insights

Bortezomib inhibits medulloblastoma growth by stabilizing the NOXA protein, leading to cell death. This mechanism offers a targeted approach for treating medulloblastoma, potentially avoiding peripheral neuropathy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Neuro-oncology

Background:

  • Bortezomib, a proteasome inhibitor, shows efficacy against medulloblastoma but causes peripheral neuropathy.
  • Understanding bortezomib's mechanism is crucial for developing safer, targeted therapies.

Purpose of the Study:

  • To elucidate the mechanism of bortezomib's anti-medulloblastoma effects.
  • To identify therapeutic strategies that specifically target the ubiquitin-proteasome system.

Main Methods:

  • Investigated upstream components of the ubiquitin-proteasome system in medulloblastoma.
  • Analyzed the role of protein NOXA stabilization by bortezomib.
  • Examined NOXA-induced caspase cleavage and oxidative stress.

Main Results:

  • Identified the pro-apoptotic protein NOXA as a key target stabilized by bortezomib.
  • Demonstrated that stabilized NOXA induces caspase cleavage and cell death under oxidative stress.
  • Bortezomib's efficacy is linked to NOXA stabilization, independent of p53 status.

Conclusions:

  • Bortezomib's anti-medulloblastoma activity is mediated by NOXA stabilization and subsequent apoptosis.
  • This mechanism provides a basis for targeted therapies in Shh-driven and other medulloblastoma subtypes.
  • Findings suggest potential for therapies independent of p53 status, mitigating side effects.

More Related Videos

Cell Subtype-specific Analysis of Neuronal Membrane Proteasome in Somatosensory Neurons09:27

Cell Subtype-specific Analysis of Neuronal Membrane Proteasome in Somatosensory Neurons

Published on: October 10, 2025

Related Concept Videos

The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...